BioScience Health Innovations Reports $415,660 Net Loss and Revenue Decline in First Half of 2026

BioScience Health Innovations, Inc. (BHIC) reported a net loss of $415,660 for the six months ended June 30, 2026, a significant decline from a net income of $884,502 during the same period in 2025. Revenue for the first half of 2026 was $1,787,310, down from $2,894,533 in the prior year. The decrease in revenue is attributed to adjustments in sales channels and marketing strategies in response to increased competition and customer feedback. Operating expenses rose to $1,592,868, compared to $1,086,121 in the previous year, driven by costs associated with transitioning to a senior exchange, enhanced marketing efforts, and increased research and development expenditures.

The company's total assets increased to $2,136,150 as of June 30, 2026, up from $1,707,181 at the end of 2025. This growth was primarily due to a rise in inventory, which reached $797,183, compared to $336,348 at the end of the previous year. Cash and cash equivalents also saw an increase, totaling $712,378, up from $661,925. However, the company reported a working capital of $1,685,704, indicating a solid liquidity position despite the operational losses.

In terms of strategic developments, BHIC has focused on enhancing its product offerings and operational infrastructure. The company has been working on its patent-pending Mods Max delivery system, which aims to improve the absorption and effectiveness of its health products. Additionally, BHIC has engaged in a significant upgrade of its accounting and enterprise resource planning systems to support future growth. The company has also completed a Regulation A round of financing, which has helped it meet the shareholder threshold required for a potential uplisting to a senior exchange.

Operationally, BHIC has made strides in solidifying its supply chain and vendor base, moving away from reliance on related-party suppliers. The company has also expanded its product portfolio to include offerings targeting various health issues, including testosterone support and cellular wellness. As of June 30, 2026, BHIC had 11,752,329 shares of common stock outstanding, reflecting an increase from 10,979,058 shares at the end of 2025, following recent capital raises.

Looking ahead, management remains optimistic about the company's potential for growth, citing the completion of operational upgrades and an expanding product footprint. BHIC aims to leverage its unique delivery system to capture market share in the growing health and wellness sectors. The company anticipates that the investments made in the first half of 2026 will translate into revenue growth and improved margins by year-end, as it continues to build its brand and product offerings in a competitive marketplace.